W
Wadih Arap
Researcher at Rutgers University
Publications - 54
Citations - 3568
Wadih Arap is an academic researcher from Rutgers University. The author has contributed to research in topics: Cancer & Phage display. The author has an hindex of 13, co-authored 54 publications receiving 3196 citations. Previous affiliations of Wadih Arap include Memorial Sloan Kettering Cancer Center & University Hospital, Newark.
Papers
More filters
Journal ArticleDOI
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
TL;DR: In vivo selection of phage display libraries was used to isolate peptides that home specifically to tumor blood vessels that enhanced the efficacy of the anticancer drug doxorubicin and reduced its toxicity.
Journal ArticleDOI
CD13/APN is activated by angiogenic signals and is essential for capillary tube formation.
Shripad V. Bhagwat,Johanna Lahdenranta,Ricardo J. Giordano,Wadih Arap,Renata Pasqualini,Linda H. Shapiro +5 more
TL;DR: It is shown that endogenous CD13/APN levels in primary cells and cell lines are up-regulated in response to hypoxia, angiogenic growth factors, and signals regulating capillary tube formation during angiogenesis, establishing the CD13-APN metalloprotease as an important regulator of endothelial morphogenesis duringAngiogenesis.
Journal Article
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Flavio Curnis,Gianluigi Arrigoni,Angelina Sacchi,Lucia Fischetti,Wadih Arap,Renata Pasqualini,Angelo Corti +6 more
TL;DR: Examination of the expression of CD13 in normal and neoplastic human tissues and cells by using two anti-CD13 monoclonal antibodies showed that a CD13 isoform expressed in tumor blood vessels could function as a vascular receptor for the NGR motif.
Journal ArticleDOI
Chemotherapy targeted to tumor vasculature
TL;DR: Vasculature-targeted chemotherapy--the destruction of tumor blood vessels with cytotoxic agents--makes use of biochemical differences between angiogenic and resting blood vessels, resulting in increased efficacy and reduced toxicity in experiments with tumor-bearing mice.
Journal ArticleDOI
Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes.
Geetanjali Sharma,Chelin Hu,Daniela I. Staquicini,Jonathan L. Brigman,Meilian Liu,Franck Mauvais-Jarvis,Franck Mauvais-Jarvis,Renata Pasqualini,Wadih Arap,Jeffrey B. Arterburn,Helen J. Hathaway,Eric R. Prossnitz +11 more
TL;DR: It is demonstrated that GPER-selective agonism is a viable therapeutic approach against obesity, diabetes, and associated metabolic abnormalities in multiple preclinical male and female models.